Subtle liver problems may contribute to the development of pulmonary arterial hypertension (PAH), suggesting complex communication between the lungs and liver along a so-called lung-liver axis, according to a study. Some people with PAH but no known liver disease showed signs of mild liver dysfunction, enhanced lung-related inflammatory processes,…
Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. “These data support the potential of our transdermal [through-the-skin] platform as a…
Higher TAGLN2 gene activity may contribute to the development of pulmonary arterial hypertension (PAH), according to a new study. Using genetic analyses and experiments in animals, researchers identified two specific DNA sites that influenced TAGLN2 expression (activity) and PAH risk. These are two sites where a chemical mark called…
Discussion
I live with both idiopathic pulmonary hypertension (PH) and scleroderma, and earlier this month, I was taught a lesson in how quickly things can unravel when you’re with people who are well-versed in one condition while you’re dealing with symptoms of the other. I traveled to Washington, D.C., to…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
